Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Liprolog 100 units/ml, solution for injection in vial
Medicines register · Ireland

Liprolog 100 units/ml, solution for injection in vial

Authorisation EU/1/01/195/001 · Eli Lilly Nederland B.V.

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Eli Lilly Nederland B.V. (all products →)
Active substance
Insulin lispro
Dosage form
Solution for injection
Route of administration
Subcutaneous use
ATC codes
A10AB, A10AB04
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
New active substance (Article 8(3) of Directive No 2001/83/EC)

Insulin lispro: supply and approvals

20 authorised products on the HPRA list contain Insulin lispro. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
Insulin lispro Sanofi: Shortage ongoing, first published 8 Dec 2025
US shortage (FDA)
Insulin Lispro Injection: resolved, updated 1 Sep 2026
Germany (BfArM)
No entry in the BfArM supply notices (checked 18 Nov 2026)
Recent EMA authorisation
Bysumlog, 6 May 2026 (biosimilar), Sandoz GmbH

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 195. The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Insulin lispro in Ireland

19 other products on the HPRA list contain Insulin lispro, from 3 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
100 units/mL Tempo Pen solution for injection in pre-filled penEli Lilly Nederland B.V.Centralised EU authorisationNot stated
200 units/mL KwikPen solution for injection in pre-filled penEli Lilly Nederland B.V.Centralised EU authorisationNot stated
Bysumlog 100 units/ml solution for injection in pre-filled penSandoz GmbHCentralised EU authorisationNot stated
HumalogEli Lilly Nederland B.V.Centralised EU authorisationNot stated
Humalog 100 units/ml solution for injection in cartridge insulin lisproEli Lilly Nederland B.V.Centralised EU authorisationNot stated
Humalog 100 units/ml solution for injection in vialEli Lilly Nederland B.V.Centralised EU authorisationNot stated
Humalog Mix25 100 units/ml suspension for injection in cartridgeEli Lilly Nederland B.V.Centralised EU authorisationNot stated
Humalog Mix25 100 units/ml suspension for injection in vialEli Lilly Nederland B.V.Centralised EU authorisationNot stated
Humalog Mix50 100 units/ml suspension for injection in cartridgeEli Lilly Nederland B.V.Centralised EU authorisationNot stated
Humalog NPLEli Lilly Nederland B.V.Centralised EU authorisationNot stated
Insulin lispro Sanofi 100 units/ml solution for injectionSanofi Winthrop IndustrieCentralised EU authorisationNot stated
LiprologEli Lilly Nederland B.V.Centralised EU authorisationNot stated

All 20 products with Insulin lispro →

Other substances in ATC group A10AB

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 4 other active substances share the group A10AB with this product:

Insulin human (12) · Insulin aspart (7) · Insulin glulisine (2) · Human insulin (recombinant dna origin) (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Eli Lilly Nederland B.V. holds 93 products on the HPRA list, with 23 different active substances; 5 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.